Peptide Tools to Study Alzheimer's Disease

About Alzheimer's Disease

Alzheimer's Disease is a neurodegenerative disease that typically begins after the age of 65 years and progresses until death. However, early-onset Alzheimer’s affects younger people, around 5% of people with Alzheimer’s are under 65.
Although the mechanisms are poorly understood, several hypotheses on the cause of Alzheimer's Disease exist. One of them is that an abnormally hyperphosphorylated tau protein initiates the disease. Another hypothesis states that the main pathogenic factor in Alzheimer's disease are amyloid plaques forming in the brain. Amyloid plaques are composed of regularly ordered amyloid fibers, a peptide fold also associated with protein misfolding diseases such as prion diseases.

Amyloid Beta Peptide

  • Beta Amyloid A4 peptide (synonyms are Aβ, Abeta, Amyloid Beta)
  • Several functions in healthy organisms, e.g. activation of kinases and cholesterol transport regulation
  • Main component of amyloid plaques
  • Arise from proteolytic processing of amyloid precursor protein (APP) involving sequential cleavages by ß- and γ-secretases
  • Represent a mixture of peptides of different lengths (up to 43 amino acids)
  • Pathological increase of ß/γ-secretase activities and diminished clearance rate initiate accumulation and aggregation of amyloid-ß peptides in the brain tissue of Alzheimer patients
  • The two isoforms Aß(1-42) and Aß(1-43) tend to aggregate
  • Resulting amyloid-ß peptide oligomers, fibrils and plaques disturb the neuronal network and show strong neurotoxic effects
  • The exact biochemical pathways underlying the pathologic effects of amyloid-ß peptides are not quite understood

JPT's Peptide Tools to Study Alzheimer:

Amyloid beta Peptides

JPT provides a broad selection of chemically synthesized amyloid-ß peptides for Alzheimer's disease research. We supply Abeta peptides of different lengths and point-mutated versions of Aß(1-42) which are known to be related to the familial forms of Alzheimer`s disease. They are provided as HFIP-films (HFIP = hexafluoroisopropanol) which removes any unwanted secondary peptide structure and pre-existing oligomeric/polymeric forms.

> Amyloid Beta A4 (abeta) Product Page

We do not have your peptide in stock? We can offer you our custom peptide synthesis service!

Selected Alzheimer Related References

"Synchrotron-Based µFTIR Study on the Effect of Alzheimer´s Aβ Amorphous and Fibrillar Aggregates on PC12 Cells"

Benseny-Cases et al., Analytical Chemistry (2018) – PMID: 29359921
"Aβ Oligomer Eliminating Compounds Interfere Successfully With pEAβ (3–42) Induced Motor Neurodegenerative Phenotype in Transgenic Mice"
Dunkelmann et al., Neuropeptides (2017)
"The Aβ Oligomer Eliminating D-enantiomeric Peptide RD2 Improves Cognition Without Changing Plaque Pathology"
van Groen et al., Science Reports (2017) – PMID: 29176708
"Selection and Characterization of Tau Binding ᴅ-Enantiomeric Peptides with Potential for Therapy of Alzheimer Disease"
Dammers et al., PLoS One (2016) – PMID: 28006031
"A Critical Role For the Self-Assembly of Amyloid-β1-42 in Neurodegeneration"
Marshall et al., Scientific Reports (2016) – PMID: 27443509
"High Affinity Binding of Monomeric, but not Oligomeric Amyloid-β to Ganglioside GM1 Containing Nanodiscs"
Thomaier et al., Biochemistry (2016)
"Limited Effects of Prolonged Environmental Enrichment on the Pathology of 5XFAD Mice"
Hüttenrauch et al., Molecular Neurobiology (2016) – PMID: 27734334
"Competitive Mirror Image Phage Display Derived Peptide Modulates Amyloid Beta Aggregation and Toxicity"
Rudolph et al., PLoS One. (2016) - PMID: 26840229
"Inhibition of the Cardiac Na+ Channel α-subunit Nav1. 5 by Propofol and Dexmedetomidine"
Stoetzer et al., Naunyn Schmiedebergs Arch Pharmacol. - PMID: 26667357
"η-Secretase Processing of APP Inhibits Neuronal Activity in the Hippocampus"
Willem et al., Nature (2015) - PMID: 26322584

Read More references



Selected Alzheimer Related Testimonial

“Our group focuses on the in vitro
study of risk factors in Alzheimer’s disease and, as we experienced that the in-house expression and production of the amyloid beta peptide is notoriously difficult, we are continuously dependent on a high quality supply of a large variety of these peptides from commercial source.  We started our collaboration with JPT with their request to test a range of their peptides for the ability to produce toxic oligomers and fibrillar networks and were impressed by the rapid supply of a very wide range of high purity peptides with excellent fibril forming properties and toxicity profiles. JPT has shown real valuable know-how and experience in the field of peptide synthesis by their ability to generate high quality preparations of amyloid beta peptide variants which are known for their difficulty to handle.”
Kerensa Broersen, Assistant Prof., Nanobiophysics Group,
University of Twente, Enschede, The Netherlands

Application Note

Synthetic Amyloid Beta Peptides Aid Alzheimer Investigation
Vandersteen et al., Application Note (2013)

More application notes

Check our list of products,
click and go.

News Highlights

--> Read more news

Quality Assurance

All production is performed according to ISO 9001:2015 standards

Stay in touch and be the first to receive the latest news!